Miranda Vinicius Carvalho, Pereira Yago Luis Gonçalves, da Paz Allane Patricia Santos, de Souza Keyla Rodrigues, da Silva Márcia Cristina Freitas, Muto Nilton Akio, Monteiro Patrick Romano, Santos Agenor Valadares, Hamoy Moises, de Medeiros Maria das Graças Freire, do Carmo Iolanda Souza, Silva Maria Eduarda Moraes, de Sousa Lima Neto José, de Mello Vanessa Jóia
Research, Teaching and Extension Laboratory in Clinical Analysis, Institute of Biological Sciences Federal University of Pará Belém Brazil.
Human and Environmental Toxicology, Tropical Medicine Nucleus Federal University of Pará Belém Brazil.
Food Sci Nutr. 2024 May 13;12(7):5131-5146. doi: 10.1002/fsn3.4162. eCollection 2024 Jul.
Diabetes mellitus is a metabolic disorder commonly associated with atherosclerosis. Plants with therapeutic potential, such as Kunth, emerge as effective alternatives for treating these diseases. Therefore, this work aims to analyze the antihyperglycemic and antidyslipidemic potential of the hydroalcoholic extract of Kunth (ELo) in alloxan-diabetic rats. Animals were treated orally: normal control, hyperglycemic control, positive control glibenclamide (5 mg/kg), and groups treated with ELo (75, 150, and 250 mg/kg). Preclinical evaluation of ELo showed hypoglycemic, hypolipidemic, hepatic, and renal protective effects. At all doses, ELo significantly reduced hyperglycemia, triglycerides, total cholesterol, low-density lipoprotein, atherogenic index, atherogenic coefficient, and cardiovascular risk index ( < .05). Elo at different doses promoted an increase in insulin release compared to untreated animals ( < .05) and showed α-glucosidase inhibitory activity ( < .05). Also, ELo (250 mg/kg group) showed maximum reduction of hyperglycemia, alanine transaminase, aspartate aminotransferase, malonaldehyde, and urea compared to the hyperglycemic and glibenclamide groups, and creatinine only compared to the hyperglycemic groups ( < .05). The promising action of ELo in the context of diabetes may be related to the synergistic action of flavonoid compounds identified in liquid chromatography, whose pharmacological capabilities have already been documented in previous studies. The mechanisms may be the stimulation of insulin release; the inhibitory activity of α-glucosidase; improving general clinical conditions; and the antioxidant effects of the extract. These findings pave the way for the future development of an herbal presentation of Kunth as a hypoglycemic and cardiovascular protector with a lipid-lowering effect.
糖尿病是一种通常与动脉粥样硬化相关的代谢紊乱疾病。具有治疗潜力的植物，如昆特草，成为治疗这些疾病的有效替代物。因此，本研究旨在分析昆特草水醇提取物（ELo）对四氧嘧啶糖尿病大鼠的降血糖和抗血脂异常潜力。动物经口给药：正常对照组、高血糖对照组、阳性对照格列本脲（5mg/kg），以及用ELo（75、150和250mg/kg）处理的组。ELo的临床前评估显示出降血糖、降血脂、肝脏和肾脏保护作用。在所有剂量下，ELo均显著降低血糖、甘油三酯、总胆固醇、低密度脂蛋白、动脉粥样硬化指数、动脉粥样硬化系数和心血管风险指数（P<0.05）。与未处理的动物相比，不同剂量的ELo促进胰岛素释放增加（P<0.05），并表现出α-葡萄糖苷酶抑制活性（P<0.05）。此外，与高血糖组和格列本脲组相比，ELo（250mg/kg组）在降低血糖、丙氨酸转氨酶、天冬氨酸转氨酶、丙二醛和尿素方面效果最佳，而在降低肌酐方面仅与高血糖组相比效果最佳（P<0.05）。ELo在糖尿病背景下的良好作用可能与液相色谱中鉴定出的黄酮类化合物的协同作用有关，其药理能力在先前的研究中已有记载。其机制可能是刺激胰岛素释放；α-葡萄糖苷酶的抑制活性；改善一般临床状况；以及提取物的抗氧化作用。这些发现为未来将昆特草作为具有降血脂作用的降血糖和心血管保护草药制剂的开发铺平了道路。
